다발성골수종 치료 시장 규모, 점유율, 성장 분석 : 치료 유형별, 투여 경로별, 질환 유형별, 최종 용도별, 지역별 - 산업 예측(2025-2032년)
Multiple Myeloma Therapeutics Market Size, Share, Growth Analysis, By Treatment Type (Chemotherapy, Targeted therapy), By Route of Administration (Oral, Parenteral), By Disease Type, By End-use, By Region - Industry Forecast 2025-2032
상품코드:1630687
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2025년 01월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 다발성골수종 치료 시장 규모는 2023년에 248억 달러로 평가되며, 2024년 263억 6,000만 달러에서 2032년에는 429억 8,000만 달러로 성장하며, 예측 기간(2025-2032년)의 CAGR은 6.3%로 성장할 전망입니다.
세계의 다발성골수종 치료 시장은 골수를 손상시키고 형질세포의 생성을 억제하는 이 혈액암의 복잡한 특성으로 인해 크게 성장하고 있습니다. 이러한 급격한 성장의 주요 요인은 인구의 고령화와 이 질환의 분자 메커니즘에 대한 인식이 높아지고 있기 때문입니다. 줄기세포 이식, 면역조절제, 프로테아좀 억제제, 모노클로널 항체 등 특수하고 강력한 치료법 개발의 혁신적 발전도 시장 확대에 박차를 가하고 있습니다. 또한 제약사들은 최첨단 치료법과 맞춤형 의료 전략을 창출하기 위한 연구에 많은 투자를 하고 있으며, 이는 치열한 경쟁 환경을 조성하고 있습니다. 제약사, 생명공학 기업 및 연구기관의 협력은 특히 단클론 항체 및 CAR-T 세포 치료와 같은 효과적이고 부작용이 적은 치료법의 도입을 촉진하고 있으며, 이는 치료 옵션에 있으며, 중요한 이정표가 되고 있습니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요의 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2024년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
다발성골수종 치료 시장 규모 : 치료 유형별
시장 개요
화학요법
표적치료
면역 조절제
줄기세포 이식
방사선 치료
기타 치료 유형
다발성골수종 치료 시장 규모 : 투여 경로별
시장 개요
경구
비경구
다발성골수종 치료 시장 규모 : 질환 유형별
시장 개요
활동성 다발성골수종
무증상 다발성골수종(Smoldering multiple myeloma)
다발성골수종 치료 시장 규모 : 최종 용도별
시장 개요
병원
전문 클리닉
홈케어 설정
기타 최종사용자
다발성골수종 치료 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2024년)
주요 시장 기업이 채택한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2024년)
주요 기업의 기업 개요
회사 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출의 전년대비 비교(2022-2024)
주요 기업 개요
Bristol Myers Squibb(USA)
Takeda Pharmaceutical Company Limited(Japan)
Amgen Inc.(USA)
Sanofi S.A.(France)
Johnson & Johnson(USA)
AbbVie Inc.(USA)
GlaxoSmithKline plc(UK)
Novartis AG(Switzerland)
Pfizer Inc.(USA)
Celgene Corporation(USA)
Karyopharm Therapeutics Inc.(USA)
Ono Pharmaceutical Co., Ltd.(Japan)
Teva Pharmaceutical Industries Ltd.(Israel)
Genmab A/S(Denmark)
Adaptive Biotechnologies Corporation(USA)
Legend Biotech Corporation(China)
MorphoSys AG(Germany)
bluebird bio, Inc.(USA)
Secura Bio, Inc.(USA)
BeiGene, Ltd.(China)
결론과 권장사항
KSA
영문 목차
영문목차
Global Multiple Myeloma Therapeutics Market size was valued at USD 24.8 billion in 2023 and is poised to grow from USD 26.36 billion in 2024 to USD 42.98 billion by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).
The global multiple myeloma therapeutics market has experienced significant growth due to the complex nature of this hematological cancer, which damages bone marrow and disrupts plasma cell production. This surge is largely attributed to an aging population and heightened awareness of the disease's molecular mechanisms. Innovative advancements in the development of specialized and potent therapies, including stem cell transplants, immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, have also fueled market expansion. Furthermore, pharmaceutical companies are heavily investing in research to create cutting-edge treatments and personalized care strategies, fostering a highly competitive landscape. Collaborations between pharma firms, biotech companies, and research institutions are driving the introduction of effective, low-side-effect therapies, notably monoclonal antibodies and CAR-T cell therapies, marking significant milestones in treatment options.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Myeloma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Multiple Myeloma Therapeutics Market Segmental Analysis
Global Multiple Myeloma Therapeutics Market is segmented by Treatment Type, Route of Administration, Disease Type, End-use and region. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted therapy, Immunomodulating agents, Stem cell transplantation, Radiation therapy and Other treatment types. Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on Disease Type, the market is segmented into Active multiple myeloma and Smoldering multiple myeloma. Based on End-use, the market is segmented into Hospitals, Specialty clinics, Homecare settings and Other end-users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Multiple Myeloma Therapeutics Market
One of the key drivers of the global Multiple Myeloma Therapeutics market is the significant advancements in treatment options. Recent discoveries in innovative therapies, including monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs (IMiDs), have proven to be highly beneficial. These cutting-edge medications are designed to specifically target cancer cells while minimizing harm to healthy cells, resulting in improved treatment efficacy. This progress has led to higher patient survival rates and enhanced quality of life following treatment. As researchers and pharmaceutical companies continue to develop these novel therapies, they further propel the growth and potential of the multiple myeloma therapeutics market.
Restraints in the Global Multiple Myeloma Therapeutics Market
The Global Multiple Myeloma Therapeutics market faces significant restraints, primarily due to the high costs associated with treatment options. Despite advancements that have enhanced patient outcomes through the introduction of various innovative therapies, the steep price tags attached to these treatments can create barriers for patients, particularly those in economically challenged regions or with limited access to healthcare services. This financial obstacle may discourage the adoption of state-of-the-art therapies, ultimately restricting the market's growth potential. Consequently, addressing affordability and accessibility is crucial to ensure that promising treatment options reach the patients who need them the most.
Market Trends of the Global Multiple Myeloma Therapeutics Market
The Global Multiple Myeloma Therapeutics market is witnessing a significant shift towards advancements in targeted therapies and immunotherapies, reflecting a broader trend of precision medicine in oncology. As traditional chemotherapy presents limitations in efficacy and adverse effects, pharmaceutical companies are increasingly investing in developing innovative treatments that specifically target malignant cells while preserving healthy tissues. This focus includes the creation of monoclonal antibodies and specialized agents designed to inhibit myeloma cell proliferation. Furthermore, cutting-edge immunotherapy approaches, such as CAR-T cell therapy, have demonstrated promising results in clinical trials, offering patients more personalized and effective treatment options, thus propelling market growth and investment in novel therapeutic modalities.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Global Multiple Myeloma Therapeutics Market Size by Treatment Type & CAGR (2025-2032)
Market Overview
Chemotherapy
Targeted therapy
Immunomodulating agents
Stem cell transplantation
Radiation therapy
Other treatment types
Global Multiple Myeloma Therapeutics Market Size by Route of Administration & CAGR (2025-2032)
Market Overview
Oral
Parenteral
Global Multiple Myeloma Therapeutics Market Size by Disease Type & CAGR (2025-2032)
Market Overview
Active multiple myeloma
Smoldering multiple myeloma
Global Multiple Myeloma Therapeutics Market Size by End-use & CAGR (2025-2032)
Market Overview
Hospitals
Specialty clinics
Homecare settings
Other end-users
Global Multiple Myeloma Therapeutics Market Size & CAGR (2025-2032)
North America (Treatment Type, Route of Administration, Disease Type, End-use)
US
Canada
Europe (Treatment Type, Route of Administration, Disease Type, End-use)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Treatment Type, Route of Administration, Disease Type, End-use)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Treatment Type, Route of Administration, Disease Type, End-use)
Brazil
Rest of Latin America
Middle East & Africa (Treatment Type, Route of Administration, Disease Type, End-use)
